



POSTER PRESENTATION

Open Access

HLA-G-specific microRNAs a novel approach for targeting tumors

Simon Jasinski-Bergner¹, Arndt Hartmann², Verena Spath², Stefan Huettelmaier³, Juliane Braun³, Juergen Bukur¹, Barbara Seliger^{1*}

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Immune inhibitory molecules on immune cells as well as on tumor cells appear to play a key role in modulating the immunogenicity of tumors and the efficacy of immunotherapies. One mediator is represented by the non-classical HLA-G antigen, which is often overexpressed in human tumors when compared to corresponding normal tissues thereby inhibiting both innate as well as adaptive immune responses. Since discordant HLA-G transcript and protein expression levels were often found in tumors of distinct origin posttranscriptional control mechanisms have been recently suggested. Indeed, different HLA-G-specific miRs have been identified, which were able to downregulate HLA-G surface expression. The miR-mediated inhibition of HLA-G enhanced the NK cell recognition. These miRs were also differentially expressed in renal cell carcinoma (RCC) versus normal kidney epithelium. Immunohistochemical analysis demonstrated of a high frequency HLA-G expression in RCC lesions, which was associated with disease progression and inversely correlated with the expression of HLA-G-specific miRs. These data postulate that HLA-G-specific miRs might be used as prognostic markers as well as potential therapeutics for targeting HLA-G expressing RCC.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P174

Cite this article as: Jasinski-Bergner et al.: HLA-G-specific microRNAs a novel approach for targeting tumors. *Journal for ImmunoTherapy of Cancer* 2013 1(Suppl 1):P174.

Authors' details

¹Martin Luther University Halle-Wittenberg, Institute of Medical Immunology, Halle, Germany. ²University of Erlangen, Institute of Pathology, Erlangen, Germany. ³Martin Luther University Halle-Wittenberg, Institute of Molecular Medicine, Halle, Germany.

¹Martin Luther University Halle-Wittenberg, Institute of Medical Immunology, Halle, Germany

Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

